Barclays Lowers Sotera Health (NASDAQ:SHC) Price Target to $17.00

Sotera Health (NASDAQ:SHC) had its target price lowered by research analysts at Barclays from $18.00 to $17.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target would suggest a potential upside of 26.11% from the stock’s current price.

Several other analysts have also recently weighed in on SHC. The Goldman Sachs Group initiated coverage on Sotera Health in a research report on Friday, December 6th. They set a “neutral” rating and a $14.00 price objective on the stock. Citigroup lifted their price target on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $17.00 price objective on shares of Sotera Health in a report on Thursday, November 21st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Sotera Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.08.

Sotera Health Trading Up 0.4 %

Shares of SHC opened at $13.48 on Tuesday. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.44. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91. The firm’s 50-day moving average price is $13.43 and its 200-day moving average price is $14.57. The firm has a market capitalization of $3.82 billion, a price-to-earnings ratio of 53.92 and a beta of 1.91.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SHC. Two Seas Capital LP grew its stake in shares of Sotera Health by 624.0% in the fourth quarter. Two Seas Capital LP now owns 2,896,136 shares of the company’s stock worth $39,619,000 after acquiring an additional 2,496,136 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Sotera Health by 14.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 299,463 shares of the company’s stock valued at $4,097,000 after purchasing an additional 37,468 shares during the last quarter. Vident Advisory LLC bought a new stake in Sotera Health during the 4th quarter valued at about $209,000. Sculptor Capital LP bought a new stake in Sotera Health during the 4th quarter valued at about $68,400,000. Finally, Quantinno Capital Management LP raised its holdings in Sotera Health by 69.0% in the fourth quarter. Quantinno Capital Management LP now owns 49,366 shares of the company’s stock worth $675,000 after buying an additional 20,149 shares during the last quarter. Hedge funds and other institutional investors own 91.03% of the company’s stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.